Diego Centeno, NP

Diego Centeno practices at Brain Health Usa in Gardena, California.

Diego Centeno's NPI, 1114608825, was assigned on July 26, 2023. Diego Centeno holds California license 95025780.

Diego Centeno's primary practice is Brain Health Usa, at 1225 W 190th St, Gardena, CA 90248 in Los Angeles County. The practice phone is (310) 515-8113.

Diego Centeno's primary practice is Brain Health Usa in Gardena, California. The medical group on file is Brain Health USA. Dmand AI also links Diego Centeno to 1 more physician office, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Diego Centeno practices, 2 sites in all. Vendor and product names are available with a free account.

Psychiatry is Diego Centeno's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Diego Centeno is licensed in California.

CMS data shows 117 Medicare services from Diego Centeno across 3 procedure codes in 2024, for 31 Medicare patients. Medicare paid $9,146 for them. Every service was in an office.

CMS counts 31 Medicare patients who saw Diego Centeno in 2024. The largest group is 65 to 74, with 18 patients. 75% of them have anxiety, and 75% have depression. 65% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Diego Centeno's median patient age at 31, with 54% women.

In 2024, Diego Centeno wrote 170 Medicare Part D claims for 26 patients. 95% of them were for generic drugs. CMS names the drug for 91 of them, across 5 drugs with 11 or more claims each, at $274 in total drug cost.

Diego Centeno accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Diego Centeno as offering telehealth.

CMS Open Payments shows 2 general payments to Diego Centeno from 2 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Neurocrine BioSciences, Inc. paid the most, $157.